Live biotherapeutic/Microbiome Based Therapeutics Market Size, Share & Trends Analysis Report By Product (VOWST (SER-109), REBYOTA, Visbiome, Other Pipeline Products), By Route of Administration (Oral Therapeutics, Rectal Therapeutics), By Target Disease Indication (Recurrent C. Difficile Infection, Dietary Management of Microbial Imbalance, Other Indications), By Distribution Channel, By End User, By Region, And Segment Forecasts, 2025-2034

Report Id: 1300 Pages: 180 Last Updated: 22 May 2025 Format: PDF / PPT / Excel / Power BI
Share With : linkedin twitter facebook

Live biotherapeutic/Microbiome Based Therapeutics Market Size is valued at USD 73.25 Bn in 2024 and is predicted to reach USD 142.81 Bn by the year 2034 at a 7.04% CAGR during the forecast period for 2025-2034.

A live microbe is utilized in a Live Biotherapeutic product to treat, prevent, or cure a disease. Microorganisms that may be beneficial to health have been discovered as the human microbiome, and its relationship to human health has come to be better understood. These microorganisms have a lot of potential for use as Live Biotherapeutic products in clinical settings. Several clinical trials are being conducted to assess their potential as a treatment. LBPs are believed to have biological effects by modulating the host-microbiota rather than directly acting on known targets or distant organs, tissues, or receptors. Importantly, LBPs will have a biological effect by influencing the local ecosystem, other microorganisms, and their interactions with the host.

Throughout the forecast period, market growth is anticipated to be driven by rising research and development efforts, as well as an expanding pipeline of microbiome-targeting therapies that are anticipated to treat a wide range of serious diseases. The development of new drugs and clinical trial activities for the treatment of diseases are being aided by ongoing innovation and technological advancements.

In 2019, 4D pharma collaborated with MSD to research and develop Live Biotherapeutics for vaccines. 4D's proprietary MicroRx® platform will be combined with MSD's expertise in developing and commercializing novel vaccines. During the forecast period, significant growth opportunities are anticipated as government funding and the R&D budget for drug development both increases. Over 640 patents focused on microbiome therapeutics were approved in 2020. The complexities occur due to a lack of expertise, specialized infrastructure, the need for astronomical capital expenditures, capacity limitations, and restrictions on ensuring compliance with good manufacturing practices (GMP).

Market Segmentation:

The Live Biotherapeutic Product Market is segmented into By Product Which consists of VOWST (SER-109), REBYOTA, Visbiome, Other Pipeline Products. Whereas, By Target Disease Indication, the segmentation includes Recurrent C. Difficile Infection, Dietary Management of Microbial Imbalance, Other Indications. The segment Route Of Administration which includes Oral and Rectal Therapeutics. The Distribution Channel segment consists of Direct Sales, Pharmacies, Online Platforms. Whereas, By End User, the market is divided into Healthcare Facilities, Home Healthcare. 

Regionally, North America is anticipated to experience brisk growth during the forecast period as a result of rising demand and the significant COVID-19 effect. Large sums of money are given to businesses to research Live Biotherapeutic ingredients and create new products.

Competitive Landscape:

Some Of The Key Players In The Live Biotherapeutic Product (LBP) Market:

  • 4D Pharma
  • Adiso Therapeutics
  • Alveolus Bio Inc
  • AOBiome Therapeutics, Inc.
  • Assembly Biosciences
  • Azitra
  • Biomica
  • Destiny Pharma
  • Destiny Pharma plc
  • EnteroBiotix Limited
  • Finch Therapeutics
  • Infant Bacterial Therapeutics AB
  • MaaT Pharma
  • Microbiotica
  • OSEL INC.
  • OxThera
  • Scioto Biosciences, Inc.
  • Second Genome
  • Seres Therapeutics
  • Servatus Limited
  • Siolta Therapeutics
  • Vedanta Biosciences
  • YSOPIA Bioscience

The Live biotherapeutic/Microbiome Based Therapeutics Market Report Scope:

Report Attribute Specifications
Market Size Value In 2024 USD 73.25 Bn
Revenue Forecast In 2034 USD 142.81 Bn
Growth Rate CAGR CAGR of 7.04% from 2025 to 2034
Quantitative Units Representation of revenue in US$ Million and CAGR from 2025 to 2034
Historic Year 2021 to 2024
Forecast Year 2025-2034
Report Coverage The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends
Segments Covered By Product, Target Disease Indication, Route Of Administration, Distribution channel, end user
Regional Scope North America; Europe; Asia Pacific; Latin America; Middle East & Africa
Country Scope U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ; France; Italy; Spain; South Korea; South East Asia
Competitive Landscape 4D Pharma, Adiso Therapeutics, Alveolus Bio Inc, AOBiome Therapeutics Inc, Assembly Biosciences, Azitra, Biomica, Destiny Pharma, Destiny Pharma plc, EnteroBiotix Limited, Finch Therapeutics, Infant Bacterial Therapeutics AB, MaaT Pharma, Microbiotica, OSEL Inc, OxThera, Scioto Biosciences Inc, Second Genome, Seres Therapeutics, Servatus Limited, Siolta Therapeutics, Vedanta Biosciences, YSOPIA Bioscience.
Customization Scope Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape.
Pricing And Available Payment Methods Explore pricing alternatives that are customized to your particular study requirements.

Segmentation Of Live biotherapeutic/Microbiome Based Therapeutics Market

Live biotherapeutic/Microbiome Based Therapeutics Market By Product

  • VOWST (SER-109)
  • REBYOTA
  • Visbiome
  • Other Pipeline Products

Live biotherapeutic/Microbiome Based Therapeutics Market By Route Of Administration

  • Oral Therapeutics
  • Rectal Therapeutics

Live biotherapeutic/Microbiome Based Therapeutics Market By Target Disease Indication

  • Recurrent C. Difficile Infection
  • Dietary management of microbial imbalance
  • Other Indications

Live biotherapeutic/Microbiome Based Therapeutics Market By Distribution Channel

  • Direct Sales
  • Pharmacies
  • Online Platforms

Live biotherapeutic/Microbiome Based Therapeutics Market By End User

  • Healthcare Facilities
  • Home Healthcare

Live biotherapeutic/Microbiome Based Therapeutics Market By Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

North America Live biotherapeutic/Microbiome Based Therapeutics Market, by Country

  • U.S.
  • Canada

Europe Live biotherapeutic/Microbiome Based Therapeutics Market, by Country,

  • Germany
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe

Asia Pacific Live biotherapeutic/Microbiome Based Therapeutics Market, by Country,

  • India
  • China
  • Japan
  • South Korea
  • Australia & New Zealand

Latin America Live biotherapeutic/Microbiome Based Therapeutics Market, by Country

  • Brazil
  • Mexico
  • Rest of Latin America

Middle East & Africa Live biotherapeutic/Microbiome Based Therapeutics Market, by Country

  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Need specific information/chapter from the report of the custom data table, graph or complete report? Tell us more.

Research Design and Approach

This study employed a multi-step, mixed-method research approach that integrates:

  • Secondary research
  • Primary research
  • Data triangulation
  • Hybrid top-down and bottom-up modelling
  • Forecasting and scenario analysis

This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.

Secondary Research

Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.

Sources Consulted

Secondary data for the market study was gathered from multiple credible sources, including:

  • Government databases, regulatory bodies, and public institutions
  • International organizations (WHO, OECD, IMF, World Bank, etc.)
  • Commercial and paid databases
  • Industry associations, trade publications, and technical journals
  • Company annual reports, investor presentations, press releases, and SEC filings
  • Academic research papers, patents, and scientific literature
  • Previous market research publications and syndicated reports

These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.

Secondary Research

Primary Research

Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.

Stakeholders Interviewed

Primary interviews for this study involved:

  • Manufacturers and suppliers in the market value chain
  • Distributors, channel partners, and integrators
  • End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
  • Industry experts, technology specialists, consultants, and regulatory professionals
  • Senior executives (CEOs, CTOs, VPs, Directors) and product managers

Interview Process

Interviews were conducted via:

  • Structured and semi-structured questionnaires
  • Telephonic and video interactions
  • Email correspondences
  • Expert consultation sessions

Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.

Data Processing, Normalization, and Validation

All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.

The data validation process included:

  • Standardization of units (currency conversions, volume units, inflation adjustments)
  • Cross-verification of data points across multiple secondary sources
  • Normalization of inconsistent datasets
  • Identification and resolution of data gaps
  • Outlier detection and removal through algorithmic and manual checks
  • Plausibility and coherence checks across segments and geographies

This ensured that the dataset used for modelling was clean, robust, and reliable.

Market Size Estimation and Data Triangulation

Bottom-Up Approach

The bottom-up approach involved aggregating segment-level data, such as:

  • Company revenues
  • Product-level sales
  • Installed base/usage volumes
  • Adoption and penetration rates
  • Pricing analysis

This method was primarily used when detailed micro-level market data were available.

Bottom Up Approach

Top-Down Approach

The top-down approach used macro-level indicators:

  • Parent market benchmarks
  • Global/regional industry trends
  • Economic indicators (GDP, demographics, spending patterns)
  • Penetration and usage ratios

This approach was used for segments where granular data were limited or inconsistent.

Hybrid Triangulation Approach

To ensure accuracy, a triangulated hybrid model was used. This included:

  • Reconciling top-down and bottom-up estimates
  • Cross-checking revenues, volumes, and pricing assumptions
  • Incorporating expert insights to validate segment splits and adoption rates

This multi-angle validation yielded the final market size.

Forecasting Framework and Scenario Modelling

Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.

Forecasting Methods

  • Time-series modelling
  • S-curve and diffusion models (for emerging technologies)
  • Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
  • Price elasticity models
  • Market maturity and lifecycle-based projections

Scenario Analysis

Given inherent uncertainties, three scenarios were constructed:

  • Base-Case Scenario: Expected trajectory under current conditions
  • Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
  • Conservative Scenario: Slow adoption, regulatory delays, economic constraints

Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.

Enter Details and Get your PDF Brochure

Name field cannot be blank!
Email field cannot be blank!(Use email format)
Designation field cannot be blank!
Company field cannot be blank!
Contact No field cannot be blank!
Message field cannot be blank!
4453
Security Code field cannot be blank!

Frequently Asked Questions

4D Pharma, Adiso Therapeutics, Alveolus Bio Inc, AOBiome Therapeutics Inc, Assembly Biosciences, Azitra, Biomica, Destiny Pharma, Destiny Pharma plc,

The Live Biotherapeutic Product (LBP) Market is expected to grow at a 7.04% CAGR during the forecast period for 2025-2034.

Product, Target Disease Indication, and Route Of Administration are the key segments of the Live Biotherapeutic Product (LBP) Market.

North American region is leading the Live Biotherapeutic Product (LBP) Market.

Live biotherapeutic/Microbiome Based Therapeutics Market Size is valued at USD 73.25 Bn in 2024 and is predicted to reach USD 142.81 Bn by the year 20
Send Me the Sample Report Enquiry Before Buying